Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blood

Showing results (331-340 of 50,514) with videos related to

Pageof 5,052
Sort By:
Blood|July 27, 2000
Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective alloantigen-presenting cellsL D Fast
Blood|July 27, 2000
Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine modelD A Vallera, D W Kuroki, A Panoskaltsis-Mortari, et al.
Blood|July 27, 2000
A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMTB Nikolic, G Zhao, K Swenson, et al.
Blood|July 27, 2000
Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liverF Park, K Ohashi, M A Kay
Blood|July 27, 2000
alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolismA M Carter, A J Catto, H P Kohler, et al.
Blood|December 6, 2001
Cross-contamination: HS-Sultan is not a myeloma but a Burkitt lymphoma cell lineH G Drexler, R A MacLeod, W G Dirks
Blood|December 6, 2001
Traumatic lumbar puncture at diagnosis and outcome in childhood acute lymphoblastic leukemiaC Kebelmann-Betzing, K Seeger, R Wolf, et al.
Blood|January 25, 2002
Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID miceJohanne Cashman, Ian Clark-Lewis, Allen Eaves, et al.
Blood|January 25, 2002
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problemRoberto Latagliata, Maria Concetta Petti, Susanna Fenu, et al.
Blood|January 25, 2002
Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBeverly J Lange, Bruce C Bostrom, Joel M Cherlow, et al.
Pageof 5,052

Showing results (331-340 of 50,514) with videos related to

Sort By:
Pageof 5,052
Blood|July 27, 2000
Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective alloantigen-presenting cellsL D Fast
Blood|July 27, 2000
Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine modelD A Vallera, D W Kuroki, A Panoskaltsis-Mortari, et al.
Blood|July 27, 2000
A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMTB Nikolic, G Zhao, K Swenson, et al.
Blood|July 27, 2000
Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liverF Park, K Ohashi, M A Kay
Blood|July 27, 2000
alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolismA M Carter, A J Catto, H P Kohler, et al.
Blood|December 6, 2001
Cross-contamination: HS-Sultan is not a myeloma but a Burkitt lymphoma cell lineH G Drexler, R A MacLeod, W G Dirks
Blood|December 6, 2001
Traumatic lumbar puncture at diagnosis and outcome in childhood acute lymphoblastic leukemiaC Kebelmann-Betzing, K Seeger, R Wolf, et al.
Blood|January 25, 2002
Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID miceJohanne Cashman, Ian Clark-Lewis, Allen Eaves, et al.
Blood|January 25, 2002
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problemRoberto Latagliata, Maria Concetta Petti, Susanna Fenu, et al.
Blood|January 25, 2002
Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBeverly J Lange, Bruce C Bostrom, Joel M Cherlow, et al.
Pageof 5,052